Stock DNA
Pharmaceuticals & Biotechnology
VND 2,818,637 Million (Small Cap)
12.00
NA
5.88%
-0.35
16.55%
1.89
Revenue and Profits:
Net Sales:
705,173 Million
(Quarterly Results - Jun 2025)
Net Profit:
74,061 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
1.05%
0%
1.05%
6 Months
-7.4%
0%
-7.4%
1 Year
-13.33%
0%
-13.33%
2 Years
-14.65%
0%
-14.65%
3 Years
-27.93%
0%
-27.93%
4 Years
-28.84%
0%
-28.84%
5 Years
-2.03%
0%
-2.03%
Traphaco JSC for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
7.13%
EBIT Growth (5y)
4.75%
EBIT to Interest (avg)
98.15
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.27
Sales to Capital Employed (avg)
1.51
Tax Ratio
20.72%
Dividend Payout Ratio
80.16%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
40.79%
ROE (avg)
19.49%
Valuation key factors
Factor
Value
P/E Ratio
12
Industry P/E
Price to Book Value
1.91
EV to EBIT
7.76
EV to EBITDA
5.88
EV to Capital Employed
2.41
EV to Sales
0.92
PEG Ratio
NA
Dividend Yield
6.03%
ROCE (Latest)
30.99%
ROE (Latest)
15.63%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
705,172.60
554,901.80
27.08%
Operating Profit (PBDIT) excl Other Income
106,833.70
79,323.90
34.68%
Interest
1,777.90
1,939.00
-8.31%
Exceptional Items
0.00
0.00
Consolidate Net Profit
74,061.10
43,451.70
70.44%
Operating Profit Margin (Excl OI)
118.50%
101.00%
1.75%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 27.08% vs -8.36% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 70.44% vs -34.83% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
2,347,221.10
2,299,235.50
2.09%
Operating Profit (PBDIT) excl Other Income
397,863.80
427,871.70
-7.01%
Interest
5,544.70
4,333.40
27.95%
Exceptional Items
0.00
0.00
Consolidate Net Profit
225,171.70
251,460.10
-10.45%
Operating Profit Margin (Excl OI)
130.60%
145.00%
-1.44%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 2.09% vs -4.16% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -10.45% vs -3.38% in Dec 2023
About Traphaco JSC 
Traphaco JSC
Pharmaceuticals & Biotechnology
Traphaco Joint Stock Company is a Vietnam-based pharmaceutical manufacturer. The Company manufactures and trades pharmaceutical products, chemicals, functional food, cosmetic products and other medical equipment and supplies. It is also involved in the cultivation and processing of drug materials, medical technology transfer, as well as the provision of consulting services in the pharmaceutical industry. Other activities of the Company include manufacturing and trading beer, wine and soft drinks (excluding bar business). As of December 31, 2012, the Company had three subsidiaries operating in the similar industry. As of the same date, it had 14 branches.
Company Coordinates 
Company Details
So 75 Yen Ninh, Quan Ba Dinh , HANOI None : None
Registrar Details






